Journal article
VDAC2 enables BAX to mediate apoptosis and limit tumor development
Hui San Chin, Mark X Li, Iris KL Tan, Robert L Ninnis, Boris Reljic, Kristen Scicluna, Laura F Dagley, Jarrod J Sandow, Gemma L Kelly, Andre L Samson, Stephane Chappaz, Seong L Khaw, Catherine Chang, Andrew Morokoff, Kerstin Brinkmann, Andrew Webb, Colin Hockings, Cathrine M Hall, Andrew J Kueh, Michael T Ryan Show all
Nature Communications | NATURE PUBLISHING GROUP | Published : 2018
Grants
Awarded by Australian National Health and Medical Research Council
Awarded by Leukaemia & Lymphoma Society (SCOR grant)
Awarded by Australian Research Council
Awarded by Victorian State Government
Funding Acknowledgements
Jason Corbin for Advia blood analysis, Crystal Stilvala, Nicole Lynch and Shannon Oliver, Carmen Epifanio, Tracey Ballinger and Marina Patsis for animal husbandry, Reema Jain, Antonia Policheni and Wenxi Zhou for assistance. We thank Andreas Strasser, Benjamin Kile, James Murphy, Marc Pellegrini, and Zina Valaydon for critical comments and input, Guillaume Lessene and Jean-Marc Garnier for A1331852, and William Craigen for WT and Vdac2<SUP>-/-</SUP> MEFs. This work was supported by scholarships to HSC from Melbourne University (MIRS, MIFRS) and the Walter and Eliza Hall Institute of Medical Research (Edith Moffatt), fellowships (1043149 to DCSH and 1090236 to DHDG) and grants (1016701, 1057742, 1059290, 1078763, 1078924, 1083077, 1113133, 1124737) from the Australian National Health and Medical Research Council, a Leukaemia & Lymphoma Society (SCOR grant 7001-13), the Australian Cancer Research Foundation, a fellowship from the Australian Research Council (FT100100791 to GD), the Cancer Council Victoria (grants-in-aid to DCSH and DHDG) and operational infrastructure grants through the Australian Government IRISS and the Victorian State Government OIS 9000220.